Ocuphire Pharma
safety findings after dilation with mydriatic agent | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
57 of 114
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
summary of safety findings there were no deaths serious aes or withdrawals due to aes of treated subjects reported aes the only occurring in of subjects treated with was conjunctival hyperemia placebo conjunctival hyperemia was observed to be mild and transient visual acuity distance and near was not adversely affected by over subjects have been treated with and evaluated at hours in the trials satisfying regulatory requirements for drug safety exposure for the acute indication | Ocuphire Pharma
Results
March 2021
secondary safety findings | Ocuphire Pharma
Related slides by other companies
Adagio Therapeutics
Results
June 2022
safety data and conclusions | Adagio Therapeutics
DICE Therapeutics
Results
March 2023
demonstrated a favorable safety and tolerability profile in psoriasis patients dice | DICE Therapeutics
Dare Bioscience
Investor Presentation
July 2023
female adverse event rates similar between groups | Dare Bioscience
BioNTech
Investor Day
June 2022
was well tolerated at the dose levels evaluated | BioNTech
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights